



Kurma Partners announces the completion of \$38.5 Million Series B financing of DNA Script

Paris, May 16, 2019 — DNA Script today announced an oversubscribed Series B fundraising of \$38.5M led by LSP, one of Europe’s largest and most experienced healthcare investment firms. BPIFrance joined the round, alongside existing investors Kurma Partners, Idinvest Partners Illumina Ventures, M Ventures and Sofinnova Partners. The proceeds will enable DNA Script to accelerate the development of the company’s first products based on its industry-leading enzymatic technology for de novo synthesis of nucleic acids. The company is prioritizing the recruitment of top talent in the U.S. for its product development and commercialization teams in preparation for product launch, as well as on expanding its Paris-based research team.

DNA Script's innovative technology provides affordable, rapid, high-quality and high-throughput production of important genomics experimental precursors, such as oligonucleotides. The technology overcomes many of the inefficiencies of today’s synthetic DNA production. It features a novel biochemical process for nucleic acids synthesis based on the use of highly efficient enzymes, thus enabling enhanced performance while minimizing the use of harsh chemicals. The product portfolio based on DNA Script’s proprietary enzymatic synthesis platform will enable molecular biology researchers to accelerate their experiments — with the goal of moving from design to results within a day for a broad range of applications.

“In less than two years since our last financing round, the DNA Script team has developed enzymatic synthesis technology at an incredibly fast pace and extended the company’s lead in this exciting and quickly expanding sector. As we announced earlier this year at the AGBT General Meeting, DNA Script was the first company to enzymatically synthesize a 200mer oligo de novo with an average coupling efficiency that rivals the best organic chemical processes in use today. Our technology is now reliable enough for its first commercial applications, which we believe will deliver the promise of same-day results to researchers everywhere with DNA synthesis that can be completed in just a few hours.” said Thomas Ybert, CEO and cofounder of DNA Script.

“Since our seed investment in 2016, we have been and remain impressed by the execution ability of DNA Script to scale its technology,” said Philippe Peltier, Partner at Kurma Partner and DNA Script’s board member. “With strong local community support and its international round of financing, DNA Script is well positioned to bring its unique technology to customers globally.”

About DNA Script

Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature’s billions of years of evolution in synthesizing DNA to enable genome scale synthesis. The Company’s technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage.

www.dnascript.co



About Kurma Partners

Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, notably through Kurma Biofund I and II, Kurma Diagnostics and strategic partnerships with prestigious European research and medical institutions.

Please contact Philippe (pp@kurmapartners.com) for further information
Kurma Team